Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Gilead Sciences will present long-term data on a novel long-acting oral combination treatment for HIV at a major upcoming conference. According to Gilead, the findings demonstrate a sustained two-year ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with drug-resistant infections in 2022. While there is still no vaccine for the ...

At least 1.4 million Kenyans are living with HIV, with approximately 21,009 people estimated to have died from AIDS-related illnesses in 2025 alone.

New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...

The World Health Organization (WHO) has released updated recommendations on HIV clinical management providing new and revised ...